Similarly, in the CheckMate 498 clinical study, PD-1 blockade in combination with radiotherapy in newly diagnosed GBM patients with unmethylated MGMT promoter failed to meet its primary endpoint of improvement in survival, as the cohort that received the alkylating chemotherapy temozolomide (TMZ) plus radiotherapy showed a longer overall survival (2). The gene discussed is PDCD1; the disease is glioblastoma.